Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug...
1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events.
2. There was a 65% overall response rate seen in...
KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia
1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion.
2. The majority of adverse events were mild, with two...
Non-vitamin K oral anticoagulants associated with superior stroke prevention over warfarin among patients with...
1. Non-vitamin K antagonist oral anticoagulants (NOACs) were associated with decreased stroke/ systemic embolism risk compared to warfarin among patients with nonvalvular atrial fibrillation...
Ruxolitinib improved glucocorticoid-refractory chronic graft-versus-host disease
1. Ruxolitinib was shown to significantly improve failure-free survival for glucocorticoid-refractory chronic graft-versus-host disease (GVHD) compared to control therapy.
2. The incidence of thrombocytopenia and...
Delayed endovascular thrombectomy associated with greater clinical benefit among patients with mismatch imaging profiles...
1. The findings supported the use of endovascular thrombectomy in patients who met criteria for either the clinical or target perfusion imaging mismatch profiles,...
Daratumumab therapy addition improved response in systemic immunoglobulin light-chain amyloidosis
1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis.
2. The daratumumab group presented...
Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma
1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone.
2. Improved median progression-free survival and estimated survival...
Lentiviral gene therapy treatment for adenosine deaminase deficiency
1. Treatment with autologous CD34+ hematopoietic stem and progenitor cells transduced with human ADA via a lentiviral vector showed sustained ADA expression in patients...
Bridging with low molecular weight heparin may not be beneficial for patients with atrial...
1. There was no significant difference found in thrombosis or bleeding outcomes for patients with atrial fibrillation or mechanical heart valves, where patients were...
Therapeutic anticoagulation increases bleeding risk without improvements in clinical outcomes in patients admitted for...
1. Therapeutic anticoagulation with rivaroxaban or enoxaparin did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation.
2. Net clinical benefit composite of...
